Japan calls for foreign medical/biotech investment:
This article was originally published in Clinica
Japan's Minister for International Trade and Industry, Kaoru Yosano, has called for additional foreign direct investment in the Japanese medical care and biotechnology sectors, noting that these are among the industries being targeted for further development. Speaking to the Council on Foreign Relations in New York, Mr Yosano noted the important role foreign investment could play in Japan's economic reform and deregulatory initiatives.
You may also be interested in...
Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.